AstraZeneca teams with oncologists, patient groups on plan to improve ovarian cancer survivalnews2022-03-15T19:36:11+00:00March 15th, 2022|Fierce Pharma|
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month datanews2022-03-15T17:43:41+00:00March 15th, 2022|Fierce Pharma|
In rare flop, Merck calls it quits on Keytruda-Lynparza combo in prostate cancernews2022-03-15T15:04:22+00:00March 15th, 2022|Fierce Pharma|
High-risk lung cancer patients aren’t getting screened, survey shows. What can the industry do?news2022-03-15T14:58:44+00:00March 15th, 2022|Fierce Pharma|
After trial flop, Exelixis drops plan to pair Cabometyx with Roche’s Tecentriq in early-stage liver cancernews2022-03-15T14:16:47+00:00March 15th, 2022|Fierce Pharma|
Indian pharma, US plastic surgeon reach deal to build $50M drug plant in Africanews2022-03-15T13:57:36+00:00March 15th, 2022|Fierce Pharma|
Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical testnews2022-03-15T13:53:31+00:00March 15th, 2022|Fierce Pharma|
MHRA request about ultrasound activation system holds up Exact Therapeutics’ solid tumor trial news2022-03-15T13:42:56+00:00March 15th, 2022|Fierce Pharma|
Novo Nordisk adds bioelectronics, biosensors and stimuli-responsive delivery devices to scope of MIT pactnews2022-03-15T13:30:52+00:00March 15th, 2022|Fierce Pharma|
Playing catch-up with J&J, Sanofi taps Blackstone for $300M to fund pivotal trial of subcutaneous Sarclisanews2022-03-15T13:04:27+00:00March 15th, 2022|Fierce Pharma|
